内科理论与实践 ›› 2022, Vol. 17 ›› Issue (06): 468-470.doi: 10.16138/j.1673-6087.2022.06.009
鱼玲玲, 吴涛(
), 白海
收稿日期:2021-10-12
出版日期:2022-12-30
发布日期:2023-02-27
通讯作者:
吴 涛 E-mail: 基金资助:
YU Lingling, WU Tao(), BAI Hai
Received:2021-10-12
Online:2022-12-30
Published:2023-02-27
中图分类号:
鱼玲玲, 吴涛, 白海. 奥布替尼治疗套细胞淋巴瘤研究进展[J]. 内科理论与实践, 2022, 17(06): 468-470.
YU Lingling, WU Tao, BAI Hai. Recent advances using orelabrutinib in the treatment of mantle cell lymphoma[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 468-470.
| [1] |
Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes[J]. CA Cancer J Clin,2016, 66(6):443-459.
doi: 10.3322/caac.21357 URL |
| [2] |
Yoon DH, Cao J, Chen TY, et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group[J]. J Hematol Oncol, 2020, 13(1): 21.
doi: 10.1186/s13045-020-00855-9 URL |
| [3] | Schieber M, Gordon LI, Karmali R. Current overview and treatment of mantle cell lymphoma[J]. F1000Res, 2018, 7: F1000. |
| [4] |
Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management[J]. Am J Hematol, 2019, 94(6): 710-725.
doi: 10.1002/ajh.25487 pmid: 30963600 |
| [5] |
Vogt N, Dai B, Erdmann T, et al. The molecular pathogenesis of mantle cell lymphoma[J]. Leuk Lymphoma, 2017, 58(7): 1530-1537.
doi: 10.1080/10428194.2016.1248965 URL |
| [6] | 毛东锋, 毛军峰, 吴涛, 等. 伊布替尼治疗套细胞淋巴瘤临床研究进展[J]. 肿瘤学杂志, 2019, 25(10): 916-919. |
| [7] |
Narurkar R, Alkayem M, Liu D. SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma[J]. Biomark Res, 2016, 4: 6.
doi: 10.1186/s40364-016-0060-9 pmid: 26949534 |
| [8] |
Zeng W, Fu K, Quintanilla-Fend L, et al. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression[J]. Am J Surg Pathol, 2012, 36(2): 214-219.
doi: 10.1097/PAS.0b013e318241f050 pmid: 22251940 |
| [9] |
Beà S, Amador V. Role of SOX11 and genetic events cooperating with cyclin D1 in mantle cell lymphoma[J]. Curr Oncol Rep, 2017, 19(6): 43.
doi: 10.1007/s11912-017-0598-1 pmid: 28466437 |
| [10] |
Jain AG, Chang CC, Ahmad S, et al. Leukemic non-nodal mantle cell lymphoma[J]. Curr Treat Options Oncol, 2019, 20(12): 85.
doi: 10.1007/s11864-019-0684-8 URL |
| [11] |
Çakar MK, Tekgündüz E, Dal MS, et al. The effect of high-dose cytarabine followed by autologous hematopoie-tic stem cell transplantation on the outcome of patients with mantle cell lymphoma[J]. J Oncol Pharm Pract, 2020, 26(2): 273-278.
doi: 10.1177/1078155219841110 URL |
| [12] |
Eskelund CW, Kolstad A, Jerkeman M, et al. 15-Year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2)[J]. Br J Haematol, 2016, 175(3): 410-418.
doi: 10.1111/bjh.14241 URL |
| [13] | Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue[J]. Blood, 2008, 112(7): 2687-2693. |
| [14] |
Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger)[J]. Lancet, 2016, 388(10044): 565-575.
doi: 10.1016/S0140-6736(16)00739-X URL |
| [15] |
Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine[J]. J Clin Oncol, 2005, 23(28): 7013-7023.
doi: 10.1200/JCO.2005.01.1825 pmid: 16145068 |
| [16] |
Bernstein SH, Epner E, Unger JM, et al. A phase Ⅱ multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma[J]. Ann Oncol, 2013, 24(6): 1587-1593.
doi: 10.1093/annonc/mdt070 pmid: 23504948 |
| [17] |
Yu H, Wang X, Li J, et al. Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma[J]. Mol Ther Oncolytics, 2021, 21: 158-170.
doi: 10.1016/j.omto.2021.03.015 URL |
| [18] | 王莹, 闫志凌, 李护君, 等. 伊布替尼单药治疗难治复发性B细胞淋巴瘤3例并文献复习[J]. 临床血液学杂志, 2020, 33(9): 644-646. |
| [19] | Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients[J]. Blood, 2013, 122(14): 2412-2424. |
| [20] |
Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways[J]. Br J Haematol, 2015, 168(5): 765-768.
doi: 10.1111/bjh.13149 URL |
| [21] |
Yasuhiro T, Sawada W, Klein C, et al. Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type Ⅱ anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab[J]. Leuk Lymphoma, 2017, 58(3): 699-707.
doi: 10.1080/10428194.2016.1201567 URL |
| [22] |
Reiff SD, Muhowski EM, Guinn D, et al. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL[J]. Blood, 2018, 132(10): 1039-1049.
doi: 10.1182/blood-2017-10-809020 pmid: 30018078 |
| [23] |
Dhillon S. Orelabrutinib: first approval[J]. Drugs, 2021, 81(4): 503-507.
doi: 10.1007/s40265-021-01482-5 pmid: 33704654 |
| [24] | Song YQ, Song YP, Liu LH, et al. Efficacy and safety of orbutinib in the treatment of patients with recurrent refractory mantle cell lymphoma[C]// The 12th National Academic Conference on Hematopoietic Stem Cell Transplantation of Chinese Medical Association, Xuzhou, 2021. |
| [25] | Xu W, Song Y, Wang T, et al. Updated results from the phase Ⅱ study of orelabrutinib monotherapy in Chinese patients with relapsed or refractory chronic lymphocytic leukemia/small cell leukemia[J]. Blood, 2020, 136(1): 26-27. |
| [26] | Zhang B, ZhaoR, LiangR, et al. Orelabrutinib, a potent and selective Bruton’s tyrosine kinase inhibitor with superior safety profile and excellent PK/PD properties[C]// AACR Annual Meeting, San Diego, 2020. |
| [27] | Kaptein A, de Bruin G, Hoek ME, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies[J]. Blood, 2018, 132 Suppl 1: 1871. |
| [28] | 中国临床肿瘤学会CSCO淋巴瘤专家委员会. 奥布替尼治疗B细胞淋巴瘤中国专家推荐临床应用指导原则(2021年版)[J]. 白血病·淋巴瘤, 2021, 30(8):455-460. |
| [29] |
Shirley M. Bruton tyrosine kinase inhibitors in B-cell malignancies[J]. Targeted Oncology, 2022, 17(1): 69-84.
doi: 10.1007/s11523-021-00857-8 URL |
| [30] | ANON. Report from the virtual American Society of Hematology (ASH) Annual Meeting, December 5th-8th, 2020[J]. Memo, 2021, 14 Suppl 1: 1-22. |
| [1] | 丁燕飞, 陈平, 罗方秀, 吴云林. 以反复上消化道出血为首发表现的套细胞淋巴瘤一例[J]. 诊断学理论与实践, 2020, 19(02): 191-194. |
| [2] | 郭晔,. 套细胞淋巴瘤的新药研究进展[J]. 内科理论与实践, 2017, 12(05): 335-338. |
| [3] | 徐星萍, 孙以隽, 阎骅,. 套细胞淋巴瘤长期生存1例[J]. 内科理论与实践, 2013, 8(03): 215-216. |
| [4] | 张莉, 沈志祥,. 套细胞淋巴瘤治疗的现状[J]. 内科理论与实践, 2007, 2(01): 61-63. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
